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Background: Zinc in human seminal plasma is divided into three types of ligands which are high (HMW),
intermediate (IMW), and low molecular weight ligands (LMW). The present study was aimed to study the effect of
Zn supplementation on the quantitative and qualitative characteristics of semen along with Zinc Binding Protein
levels in the seminal plasma in asthenozoospermic patients.
Methods: Semen samples were obtained from 37 fertile and 37 asthenozoospermic infertile men with matched
age. The subfertile group was treated with zinc sulfate, every participant took two capsules per day for three
months (each one 220mg). Semen samples were obtained (before and after zinc sulfate supplementation). After
liquefaction seminal fluid at room temperature, routine semen analyses were performed. For determination of the
amount of zinc binding proteins, the gel filtration of seminal plasma on Sephadex G-75 was performed. All the
fractions were investigated for protein and for zinc concentration by atomic absorption spectrophotometry.
Evaluation of chromatograms was made directly from the zinc concentration in each fraction.
Results: A significant high molecular weight zinc binding ligands percentage (HMW-Zn %) was observed in seminal
plasma of fertile males compared with subfertile males. However, seminal low molecular weight ligands (LMW-Zn)
have opposite behavior. The mean value of semen volume, progressive sperm motility percentage and total normal
sperm count were increased after zinc sulfate supplementation.
Conclusions: Zinc supplementation restores HMW-Zn% in seminal plasma of asthenozoospermic subjects to
normal value. Zinc supplementation elevates LMW-Zn% in seminal plasma of asthenozoospermic subjects to more
than normal value.
Trial registration: ClinicalTrials.gov identifier NCT01612403
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Infertility is defined as lack of ability to conceive within
one year of unprotected intercourse with the same partner
[1]. It is estimated that nearly 8-‐12% of couples are infer-
tile [2]. There are several causes leading to male infertility,
like radiation, cigarette smoking, varicocele, antibacterial
drugs, infections, obstructive lesions, therapeutic drugs,
trauma, genitourinary infection, environmental agents,
oxidative stress, and nutritional deficiency of trace ele-
ments like, selenium and zinc [3,4]. Zn is the following* Correspondence: mahmoudhadwan@gmail.com
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reproduction in any medium, provided the oronly to iron as the most abundant element in the body.
Although, Zinc is found in red meat, white meat, fish, and
milk; the World Health Organization (WHO) approxi-
mates that one-third of world population is deficient in Zn
[5]. Zinc and citrate are excreted from the prostate gland
as a low molecular weight complex, for that explanation,
it is estimated that zinc levels in seminal plasma typically
represent the prostatic secretory function. After ejacula-
tion, halve quantity of this complex is redistributed and
linkage to medium and high molecular weight compounds
which generated from the seminal vesicles [6]. Zn is vital
to reproductive potential. It has been reported to protect
sperm from bacteria and chromosomes damage [7]. Also,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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atogenesis, and sperm physiology [8]; it conserves gen-
omic integrity in the sperm and stabilizes connection of
sperm head to tail [9]. Deficiency of Zn is associated with
hypogonadism and insufficient growth of secondary sex
characteristics in human beings [10]. Low seminal Zn
levels were coupled with a decrease in fertilizing ability of
sperm [11] and decreased the synthesis of testosterone
[12,13]. Also, it can cause atrophy of the seminiferous
tubules in the rat, and that leads to malfunction in sperm-
atogenesis and impotence [14].
The binding of zinc with some proteins, such as
metallothioneins [MT] and α-2 macroglobulin [α-2M] is
fundamental immune efficiency for the duration of age-
ing and in age-related diseases. These proteins may turn
from a function of protection against cellular oxidative
injury. Furthermore, zinc-binding proteins regain their
essential role of cellular protection against oxidative
damage after zinc supplementation [15].
Studies have shown that oral zinc supplementation
develops sperm count, motility and the physical charac-
teristics of sperm in animals [16,17] and also, in some
groups of infertile men [18,19]. The present study was
conducted to study the effect of Zn supplementation on
the quantitative and qualitative characteristics of semen
along with Zinc Binding Protein levels in the seminal
plasma of asthenozoospermic patients.
Methods
Patients
This study includes 37 subfertile male partners between
July 2011 to April 2012, from couples who had consulted
the infertility clinic of the Babil hospital of maternity
(Hilla city/IRAQ). The approval of the institutional re-
search ethics committee, and consent of every patient
included in the study was obtained. A detailed medical
history was taken and physical examination was per-
formed. Subjects currently on any medication or antioxi-
dant supplementation were not included. The inclusion
criteria were asthenozoospermia, the absence of endocri-
nopathy, varicocele, and female factor infertility. Smo-
kers and alcoholic men were excluded from the study
because of their recognized high seminal ROS levels and
decreased antioxidant levels. The selection criteria of fer-
tile group were the absence of asthenozoospermia, endo-
crinopathy, varicocele, and have a birth in the last year.
Semen analysis
Semen samples were obtained from 37 fertile (age 31.4
±4.2 year) and 37 subfertile (age 32.3±3.68 year) men with
asthenozoospermia by masturbation after three days of
sexual abstinence. The subfertile group was treated with
zinc sulfate, every participant took two capsules of zinc
sulfate per day for three months (each one 220mg). Semensamples were obtained (before and after zinc sulfate sup-
plementation). After liquefaction seminal fluid at room
temperature, routine semen analyses including semen vol-
ume, pH, concentration, sperm motility, normal sperm
morphology and round cell were performed according to
2010 WHO recommendation [20].
An aliquot of the remaining semen was centrifuged at
2000 g for 15 min and the seminal plasma was collected
immediately. These fractions were classified into three
groups called group I (healthy donors), group II (patients
before treatment) and group III (patients after treat-
ment) respectively. After that, the samples were frozen
(−20°C) until analyzed.
Chemicals
All reagents and chemicals were of analytical grade and
obtained from standard commercial suppliers.
Biochemical procedures
Gel filtration
For determination of the amount of zinc binding pro-
teins, the gel filtration of seminal plasma on Sephadex
G-75 was performed according to Arver method exactly
[21]. Sephadex G-75 was packed in a 2.5×40 cm glass
column and equilibrated and eluted with 0.05 M Tris
buffer containing 0.15 M NaCl, pH 7.4. The elution was
collected at a flow rate of 10–16 ml cm –2 h –1 in 50
fractions. All the fractions were investigated for protein
(A 280nm) and for zinc concentration by atomic absorp-
tion spectrophotometry (shimadzu AA 6300). Homogen-
eity of gel packing and void volume (Vo) was checked
with Dextrane Blue 2000 (Pharmacia, Sweden). Total
column volume was calculated from column dimensions.
Evaluation of chromatograms were made directly from
the zinc concentration in each fraction and the peaks
were referred to as I, II, and III or HMW, IMW and
LMW (High, Intermediate and Low molecular Weight
zinc binding protein) respectively. The area of peak was
calculated by Simpson’s 1/3 rule [22].
Statistical analysis





The results in Table (1) indicate the baseline, characteristics
of the semen parameters are depicted in the fertile and sub-
fertile (before and after treatment with zinc sulfate) groups.
These parameters were significantly decreased in infertile
group compared with healthy donors group. However, the









Healthy donors 2.8±0.43 83±16 68±12 77±5
Patients before treatment 1.72±0.66* 68±17* 22±7* 66±12
Patients after treatment 2.38±0.6** 70±17 38±8** 71±8**
Sn1*: significance versus group I (Healthy donors).
Sn2 **: significance versus group II (Patients before treatment).
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(return to normal value) after zinc sulfate supplementation.
The common appearance of the zinc distribution be-
tween different ligands in human seminal plasma as discov-
ered by gel filtration on Sephadex G-75 is demonstrated in
Figure 1. The HMW (peak I) and LMW (peak III) ligands
have characteristic chromatographic properties but the
IMW ligands (peak II) show an inconsistent pattern [21].
We observed a significant higher semen high molecu-
lar weight zinc binding ligands percentage (HMW-Zn %)
in fertile males compared with subfertile males; however,
zinc supplementation restores this percentage in the
subfertile men to the normal ranges. On the other hand,
seminal low molecular weight ligands (LMW-Zn) haveFigure 1 Above: Distribution of zinc in one sample of human semina
(patients before treatment) and group III (patients after treatment)) s
results from 9 semen samples of each group subjected to gel filtration as sopposite behavior. IMW- Zn% decreased significantly in
semen of patients of asthenozoospermia.Discussion
The concentration of zinc in human seminal plasma is
higher than blood and tissues [23]. Zinc is part of copper
-zinc superoxide dismutase and several proteins involved
in the cell differentiation (eg, glycoprotein IIb/IIIa) as
well as the factors activation such as KS-1, WT-1, Finb,
TRAF-2, and ZEB [24-26]. Zinc deficiency affects
reproduction adversely in view of the fact that all the
hormones and a wide range of enzymes involved in
reproduction are receptive to zinc. Principally, zinc isl plasma of each group (group I (healthy donors), group II
ubjected to gel filtration on Sephadex G-75. Below: The combined
hown above.
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hormones and follicle-stimulating hormone [27].
There have been conflicting clinical reports on the effect
of seminal zinc on sperm count, motility and the physical
characteristics of sperm. Several studies have pointed out
that there are no significant difference between Zn levels
in fertile and infertile men [28-31] but furthers found a
significant difference between them [32-34]. Danscher
et al. [35] indicated a high concentration of Zn to be
linked with poor motility of sperm. Also, Carpino et al.
[36] have reported high sperm zinc content to be asso-
ciated with oligoasthenozoospermic specimens. On the
other hand, others have observed a high zinc content in
seminal plasma to be correlated with good physical char-
acteristics of sperm such as sperm count [31,32], motility
[33,37], and normal morphology [33,38].
As a result, total seminal zinc concentration may not
be a useful indicator of the zinc fraction associated with
physical characteristics of sperm and a more appropriate
marker of the ion bioavailability should be utilized to
assess its relationship to sperm functions. The best
proof is zinc binding protein because all the previous
studies as well as this study observed that zinc binding
protein correlated with sperm functions such as count
and motility [28,33].
Seminal zinc has been investigated by measuring the
amount of zinc bound to vesicular high, intermediate and
low molecular weight protein. HMW-Zn% was decreased
in asthenozoospermic subjects. While, low zinc binding
protein LMW-Zn% exhibits reverse behavior, so it
decreased in healthy fertile men and increased in subfertile.
The mechanism by which HMW-Zn% in seminal
plasma of asthenozoospermic subjects is depleted has
not been fully explained in previous studies. Different
studies have shown that Zn has an important role in
scavenging reactive oxygen species (ROS) owing to it
has antioxidative properties [39-41]. Elevated levels of
ROS were detected in the semen of high percentage ofFigure 2 The coagulation and liquefaction of human semen.infertile patients, which affected sperm function [42]. As
a result, to this elevation of ROS levels, Zn levels may be
reduced in seminal plasma of asthenozoospermic sub-
jects, and that leads to an increase in oxidation of
HMW-Zn binding proteins in seminal plasma. The last
processes are associated with abnormal sperm para-
meters. Zinc supplementation restores HMW-Zn% in
seminal plasma of asthenozoospermic subjects to normal
value, may be because its role in polymeric organization
of macromolecules likes protein synthesis and cell div-
ision [43] or because its ability to influence the process
of spermatogenesis and maintains the ability of sperm
nuclear chromatin to undergo de-condensation and
modulates sperm functions [44].
LMW-Zn% is elevated in seminal plasma of asthenozoos-
permic patients may be because increment the levels of
semenogelin in seminal plasma of asthenozoospermic sub-
jects. Martinez-Heredia et al. [45] used 2DE-MS to
recognize 17 protein spots with differential expression
levels between asthenozoospermic samples and controls.
Markedly, semenogelin has been shown to elevate in asthe-
nozoospermic samples. Zhao et al. [46] demonstrated that
semenogelin I precursor is recognized as four kinds of pro-
tein. Two of these proteins characterized 14 kDa fragments
and the other two were 17 kDa fragments. All of these pro-
teins were highly expressed in asthenozoospermic patients.
Before this scientific finding, Yoshida et al. [47] documen-
ted that a 14 kDa fragment of semenogelin has an inhibi-
tory consequence on ejaculated spermatozoa. Semenogelin
is secreted from the seminal vesicle at ejaculation and es-
tablish major structural components of coagulated human
semen. It is defined as a sperm motility inhibitor, which is
classified into two types of intermediate molecular weight
zinc binding protein (IMW-ZnBP), [because it has molecu-
lar weight more than 3000 and less than 80 000], the first
Semenogelin I (a protein of molecular weight (MW) 52
kDa) and Semenogelin II (existed as two forms of a Sg I-
related protein with MWs of 71 and 76 kDa) [48,49]. After
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antigen (PSA) act to cleave SgI and SgII molecules (inter-
mediate molecular weight zinc binding protein IMW-
ZnBP) to produce soluble fragments (Low molecular weight
zinc binding protein LMW-ZnBP) [50]. PSA is accumulated
in the prostate in a Zn2+ -inhibited type. However, PSA is
activated after mixing with Semenogelin, which has a
higher Zn2+ -binding affinity than PSA [51]. In correspond-
ing to this liquefaction, the spermatozoa become regularly
more motile, as shown in Figure 2.
Zinc supplementation elevates LMW-Zn% in seminal
plasma of asthenozoospermic subjects to more than nor-
mal value, that’s may be because its enhancement the syn-
thesis of metallothioneins (Low molecular weight zinc
binding protein) [52,53]. The increment of LMW-Zn%
not coming from the degradation of semenogelin because
Zn2+ acts to inhibit the protease activity of prostate-
specific antigen [54]. The increment of LMW-Zn% after
supplementation is not harmful to spermatozoa because
it’s not generating from the degradation of semenogelin,
i.e. it’s not contain 14 kDa fragment of semenogelin which
has an inhibitory effect on ejaculated spermatozoa.
Conclusions
Zinc supplementation restores HMW-Zn% in seminal
plasma of asthenozoospermic subjects to normal value.
Zinc supplementation elevates LMW-Zn% in seminal
plasma of asthenozoospermic subjects to more than nor-
mal value.
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